Lakewood-Amedex Pursues Nasdaq Direct Listing, Raises $7.5M in Private Placement

TL;DR

**LABT's direct listing is a high-risk, high-reward play, with potential for extreme volatility and dilution, making it a speculative bet on Nasdaq approval and future biotech success.**

AI Summary

Lakewood-Amedex Biotherapeutics Inc. (LABT) is pursuing a direct listing on the Nasdaq Capital Market for 4,689,177 shares of common stock, with no firm-commitment underwriting. The company will not receive any proceeds from the sale of these shares by existing stockholders. Concurrently, LABT has secured agreements to sell 937,500 shares of Series C Preferred Stock in a private placement for gross proceeds of $7,500,000, with a stated value of $10.00 per share. The Series C Preferred Stock is convertible into common stock at a variable price, not lower than $1.00. RBW Capital Partners LLC, acting as a financial advisor, will receive 272,219 shares of common stock, representing 1.75% of fully diluted shares, for assisting with the direct listing, and a 7.0% placement fee on the private placement proceeds. The listing on Nasdaq is a critical condition for the offering, and failure to secure it will result in termination of the direct listing. The company is an 'emerging growth company' and 'smaller reporting company,' allowing for reduced public company reporting requirements.

Why It Matters

This S-1/A filing signals Lakewood-Amedex's intent to access public markets via a direct listing, a less traditional route than an IPO, which could lead to higher price volatility for investors. The concurrent $7.5 million private placement provides crucial capital, but the conversion terms of the Series C Preferred Stock, with a variable conversion price as low as $1.00, could dilute existing common stockholders. The success of this offering hinges entirely on Nasdaq approval, posing a significant risk to the company's market debut and its ability to compete in the capital-intensive biotherapeutics sector.

Risk Assessment

Risk Level: high — The risk level is high due to the novel direct listing method, which lacks firm-commitment underwriting and could lead to more volatile trading volumes and prices. Furthermore, the listing on Nasdaq is a 'condition of the offering,' meaning if the application is not approved, the direct listing will be terminated, as stated in the filing. The variable conversion price of the Series C Preferred Stock, potentially as low as $1.00, also presents a significant dilution risk to common stockholders.

Analyst Insight

Investors should exercise extreme caution and thoroughly review the 'Risk Factors' section before considering an investment. Given the potential for high volatility and the critical dependency on Nasdaq approval, a 'wait and see' approach until the listing is confirmed and initial trading patterns emerge is advisable.

Key Numbers

• 4,689,177 — Shares of Common Stock (Number of shares registered for resale by existing stockholders in the direct listing)
• $7,500,000 — Gross Proceeds (Amount raised from the private placement of Series C Preferred Stock)
• 937,500 — Shares of Series C Preferred Stock (Number of shares sold in the private placement)
• $10.00 — Stated Value per Series C Preferred Share (The stated value of each Series C Preferred Stock share)
• 272,219 — Advisory Shares (Number of common shares to be issued to RBW Capital Partners LLC as compensation)
• 1.75% — Advisory Share Percentage (Percentage of current fully diluted shares outstanding represented by Advisory Shares)
• 7.0% — Placement Fee (Percentage of gross proceeds from the private placement paid to RBW Capital Partners LLC)
• $1.00 — Floor Price for Series C Conversion (The minimum conversion price for Series C Preferred Stock into Common Stock)

Key Players & Entities

• Lakewood-Amedex Biotherapeutics Inc. (company) — Registrant and issuer of securities
• Nasdaq Capital Market (regulator) — Proposed listing exchange for common stock
• RBW Capital Partners LLC (company) — Financial advisor and placement agent for the direct listing and private placement
• Kelvin Cooper (person) — Agent for Service for Lakewood-Amedex Biotherapeutics Inc.
• Joseph M. Lucosky, Esq. (person) — Legal counsel from Lucosky Brookman LLP
• Dawson James Securities, Inc. (company) — Broker-dealer for the sale of Series C Preferred Stock
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• Nevada (company) — State of incorporation for Lakewood-Amedex Biotherapeutics Inc.

FAQ

Risk Factors

• Reliance on Private Placement Proceeds [high — financial]: The company's ability to fund its operations and development is heavily reliant on the successful completion of the $7,500,000 private placement of Series C Preferred Stock. Failure to secure these funds would significantly impact the company's financial stability and future prospects.
• Direct Listing Uncertainty [high — market]: The direct listing on Nasdaq is a critical condition for the offering. If the listing is not approved, the direct listing will be terminated, leaving existing stockholders unable to sell their shares through this mechanism.
• No Proceeds to Company from Direct Listing [medium — financial]: The direct listing involves the sale of 4,689,177 shares by existing stockholders, and the company will not receive any proceeds from this transaction. This means the company's cash position will not be directly improved by the direct listing.
• Variable Conversion Price of Preferred Stock [medium — financial]: The Series C Preferred Stock is convertible into common stock at a variable price, not lower than $1.00. This variability introduces uncertainty regarding the future dilution and the effective price paid by private placement investors.
• Significant Advisory Fees [medium — financial]: RBW Capital Partners LLC is to receive 272,219 shares of common stock and a 7.0% placement fee on the $7,500,000 private placement. This represents a substantial cost to the company and its existing shareholders in terms of dilution and cash outflow.

Industry Context

Lakewood-Amedex Biotherapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry. The sector is characterized by long development cycles, significant R&D costs, and high failure rates. Companies often rely on external financing, such as private placements and public offerings, to fund their operations and clinical trials. The success of biotechs is heavily dependent on regulatory approvals and the ability to demonstrate clinical efficacy and safety.

Regulatory Implications

As a biopharmaceutical company, LABT is subject to stringent regulations from bodies like the FDA. The S-1/A filing itself is a regulatory requirement for public offerings. The company's status as an 'emerging growth company' and 'smaller reporting company' allows for some leniency in reporting, but core regulatory compliance for drug development remains critical.

What Investors Should Do

1. Evaluate the success of the Series C Preferred Stock private placement.
2. Monitor the Nasdaq listing approval status.
3. Assess the dilution impact from the Series C Preferred Stock conversion.
4. Understand the company's cash burn rate and runway post-financing.

Glossary

Direct Listing

A process where a company lists its shares directly on a stock exchange without the involvement of underwriters. Existing shareholders can sell their shares directly to the public. (LABT is pursuing a direct listing for existing shares, meaning the company itself will not raise capital from this transaction.)

Emerging Growth Company

A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. These companies are allowed to take advantage of certain exemptions from reporting requirements. (LABT qualifies as an EGC, allowing for reduced public company reporting obligations.)

Smaller Reporting Company

A non-accelerated filer or a non-large accelerated filer with a public float of less than $250 million. Similar to EGCs, they have reduced disclosure requirements. (LABT's status as an SRC further reduces its public reporting burden.)

Series C Preferred Stock

A class of preferred stock, in this case, sold in a private placement. It has specific terms, including a stated value and a conversion mechanism into common stock. (This is the instrument through which LABT is raising $7,500,000 in new capital.)

Stated Value

The nominal value assigned to a share of preferred stock, often used in calculating liquidation preferences and conversion rights. (The Series C Preferred Stock has a stated value of $10.00 per share.)

Fully Diluted Shares

The total number of shares that would be outstanding if all convertible securities, options, and warrants were exercised. (The advisory shares issued to RBW Capital Partners are calculated as 1.75% of the current fully diluted shares.)

Year-Over-Year Comparison

This S-1/A filing represents a significant transition for Lakewood-Amedex Biotherapeutics Inc., as it outlines a direct listing and a concurrent private placement. As this is an initial filing for these specific transactions, a direct comparison of key metrics like revenue growth, margin changes, or new risks against a prior year's filing is not applicable. The focus is on the capital-raising activities and the path to public market access.

Key Financial Figures

• $10.00 — rs in a private placement at a price of $10.00 per share, such issuance to occur prior
• $7,500,000 — C Preferred Stock for gross proceeds of $7,500,000. The Series C Preferred Stock has a sta
• $10 — ents, will be equal to the lower of (i) $10.00, or (ii) 80% of the average of the c
• $1.00 — ll not be lower than the floor price of $1.00. The Series C Preferred Stock and under

Filing Documents

• ea0248668-12.htm (S-1/A) — 6676KB
• ea024866812ex23-1.htm (EX-23.1) — 2KB
• ea024866812ex23-2.htm (EX-23.2) — 2KB
• timage_001.jpg (GRAPHIC) — 547KB
• tbarchart_001.jpg (GRAPHIC) — 133KB
• timage_002.jpg (GRAPHIC) — 227KB
• tlinechart_001.jpg (GRAPHIC) — 350KB
• timage_003.jpg (GRAPHIC) — 347KB
• timage_004.jpg (GRAPHIC) — 377KB
• timage_005.jpg (GRAPHIC) — 425KB
• tbarchart_002.jpg (GRAPHIC) — 383KB
• tbarchart_003.jpg (GRAPHIC) — 406KB
• tbarchart_004.jpg (GRAPHIC) — 294KB
• tbarchart_009.jpg (GRAPHIC) — 308KB
• tbarchart_005.jpg (GRAPHIC) — 363KB
• tbarchart_006.jpg (GRAPHIC) — 253KB
• tbarchart_007.jpg (GRAPHIC) — 232KB
• tbarchart_008.jpg (GRAPHIC) — 267KB
• 0001213900-26-037938.txt ( ) — 13446KB

RISK FACTORS

RISK FACTORS   12

USE OF PROCEEDS

USE OF PROCEEDS   41 DIVIDEND POLICY   42 CAPITALIZATION   43 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   45

BUSINESS

BUSINESS   57 MANAGEMENT   100 EXECUTIVE AND DIRECTOR COMPENSATION   106 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS   112 PRINCIPAL AND REGISTERED STOCKHOLDERS   114

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK   117 PLAN OF DISTRIBUTION   121 SHARES ELIGIBLE FOR FUTURE SALE   124 SALE PRICE HISTORY OF COMMON STOCK   127 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS   128 LEGAL MATTERS   134 EXPERTS   134 WHERE YOU CAN FIND MORE INFORMATION   134 INDEX TO FINANCIAL STATEMENTS   F-1 i Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward -looking statements.” All statements other than statements of historical facts contained in this prospectus may be forward -looking statements. These forward -looking statements can generally be identified by the use of forward -looking terminology, including the terms “believes,” “estimates,” “continues,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” “would” or “should” or, in each case, their negative or other variations or comparable terminology. They appear in a number of places throughout this prospectus, and include statements regarding our intentions, beliefs, or current expectations concerning, among other things, our results of operations, financial condition, liquidity, prospects, growth, strategies, future acquisitions, and the industry in which we operate. By their nature, forward -looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We believe that these risks and uncertainties include, but a

View Full Filing

View this S-1/A filing on SEC EDGAR